[Federal Register Volume 79, Number 52 (Tuesday, March 18, 2014)]
[Notices]
[Pages 15136-15137]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-05867]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Start-Up Exclusive Patent License Agreement: 
Treatment of Breast Cancer, Prostate Cancer, Ewing Sarcoma, and Thymoma

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant of a Start-Up Exclusive 
Patent License Agreement to Paris Therapeutics, a company having a 
place of business in Santee, CA, to practice the inventions embodied in 
the following patent applications:
1. U.S. Provisional Patent Application. No. 61/474,664, filed April 12, 
2011; HHS Ref. No.: E-068-2011/0-US-01; Titled: Human Monoclonal 
Antibodies that bind insulin-like growth factor (IGF) I and II; 
Inventors: Dimiter S. Dimitrov (NCI), Qi Zhao (NCI), and Zhongyu Zhu 
(NCI)
2. PCT Application No. PCT/US2012/033128, filed April 11, 2012; HHS 
Ref. No.: E-068-2011/0-PCT-02; Titled: Human Monoclonal Antibodies that 
bind insulin-like growth factor (IGF) I and II; Inventors: Dimiter S. 
Dimitrov (NCI), Qi Zhao (NCI), and Zhongyu Zhu (NCI)

3. U.S. Patent Application No. 14/111,507, filed October 11, 2013; HHS 
Ref. No.: E-068-2011/0-US-03; Titled: Human Monoclonal Antibodies that 
bind insulin-like growth factor (IGF) I and II; Inventors: Dimiter S. 
Dimitrov (NCI), Qi Zhao (NCI), and Zhongyu Zhu (NCI)

The patent rights in these inventions have been assigned to the 
Government of the United States of America. The territory of the 
prospective Start-Up Exclusive Patent License Agreement may be 
worldwide, and the field of use may be limited to ``Antibodies against 
Insulin-like Growth Factors IGF-I and IGF-II for the treatment of 
breast cancer, prostate cancer, Ewing sarcoma, and thymoma.''

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
April 2, 2014 will be considered.

ADDRESSES: Requests for copies of the patent application(s), inquiries, 
comments, and other materials relating to the contemplated Start-Up 
Exclusive Patent License Agreement should be directed to: Whitney A. 
Hastings, Ph.D., Licensing and Patenting Manager, Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, MD 20852-3804; Telephone: (301) 451-7337; 
Facsimile: (301) 402-0220; Email: [email protected]. A signed 
confidentiality nondisclosure agreement will be required to receive 
copies of any patent applications that have not been published or 
issued by the United States Patent and Trademark Office or the

[[Page 15137]]

World Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: This technology describes fully human 
monoclonal antibodies that have been affinity maturated against IGF-I 
and IGF-II and display extremely high affinities for IGF-I and IGF-II 
in the picoM range. Some of these antibodies potently inhibited signal 
transduction mediated by the IGF-1R interaction with IGF-I and IGF-II 
and blocked phosphorylation of IGF-IR and the insulin receptor. In 
addition, they inhibited migration in the MCF-7 breast cancer cell line 
at the picoM range. Therefore, these antibodies could be used to 
prevent binding of IGF-I and/or IGF-II to its concomitant receptor 
IGFIR, consequently, modulating diseases such as cancer.
    The prospective Start-Up Exclusive Patent License Agreement is 
being considered under the small business initiative launched on 
October 1, 2011 and will comply with the terms and conditions of 35 
U.S.C. 209 and 37 CFR part 404. The prospective Start-Up Exclusive 
Patent License Agreement may be granted unless the NIH receives written 
evidence and argument, within fifteen (15) days from the date of this 
published notice, that establishes that the grant of the contemplated 
Start-Up Exclusive Patent License Agreement would not be consistent 
with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    Complete applications for a license in the prospective field of use 
that are filed in response to this notice will be treated as objections 
to the grant of the contemplated Start-Up Exclusive Patent License 
Agreement. Comments and objections submitted to this notice will not be 
made available for public inspection and, to the extent permitted by 
law, will not be released under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: March 14, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-05867 Filed 3-17-14; 8:45 am]
BILLING CODE 4140-01-P